BridgeBio presenting results of Phase 3 study of acoramidis in ATTR-CM

BridgeBio Pharma announced that outcomes data through 42 months from the ongoing long-term open-label extension of ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be shared in a featured science oral presentation at the American Heart Association Scientific Sessions taking place in Chicago on November 16 – 18. In addition to the presentation, BridgeBio was selected to share three posters in moderated poster sessions on ATTR-CM.